摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(2-氨基苯基)-4-氧代丁酸乙酯 | 253264-94-7

中文名称
4-(2-氨基苯基)-4-氧代丁酸乙酯
中文别名
——
英文名称
ethyl 4-(2-aminophenyl)-4-oxobutanoate
英文别名
4-(2-amino-phenyl)-4-oxo-butyric acid ethyl ester
4-(2-氨基苯基)-4-氧代丁酸乙酯化学式
CAS
253264-94-7
化学式
C12H15NO3
mdl
——
分子量
221.256
InChiKey
AKKZWDPNRFZFEX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    378.1±22.0 °C(Predicted)
  • 密度:
    1.147±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    16
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    69.4
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-(2-氨基苯基)-4-氧代丁酸乙酯 在 sodium hydride 作用下, 反应 3.0h, 以81%的产率得到1H-[1]-苯并氮杂卓-2,5(3H,4H)-二酮
    参考文献:
    名称:
    的咪唑并发现[1,5-一个] [1,2,4] -三唑并[1,5- d ] [1,4]苯并二氮杂骨架作为一种新型的,有效的和选择性的GABA甲α5反相激动剂系列
    摘要:
    通过迭代设计周期,我们发现了许多新颖的新类,其中咪唑并[1,5- a ] [1,2,4]-三唑并[1,5- d ] [1,4]苯并二氮杂被认为是最有前途的GABA一个α5反相激动剂类的认知提高的潜力。此类具有适度的亚型结合选择性和反向激动作用,并具有最有利的分子特性,可进一步优化针对中枢神经系统(CNS)的药物。
    DOI:
    10.1016/j.bmcl.2009.07.153
  • 作为产物:
    参考文献:
    名称:
    N-磺酰基2-氨基苯甲醛与烯烃之间的RhIII催化的加氢酰化反应
    摘要:
    烯烃的金属催化加氢酰化表示C中的重要原子的经济的合成方法 ħ活化。N-磺酰基2-氨基苯甲醛与共轭和脂肪族烯烃的偶联首次实现了高效率的Rh III Cp *催化的加氢酰化反应,从而合成了各种芳基酮。有时,当使用银(I)氧化剂时会发生氧化偶联。
    DOI:
    10.1002/chem.201400022
点击查看最新优质反应信息

文献信息

  • Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
    申请人:——
    公开号:US20030055042A1
    公开(公告)日:2003-03-20
    The present invention is a compound of formula 1 wherein R 1 is halogen or lower alkyl; R 2 is hydrogen, lower alkyl, cycloalkyl, —(CH 2 ) m -phenyl, wherein the phenyl ring may be substituted by lower alkoxy, or is —(CH 2 ) m -indolyl; R 3 is —C(O)O-lower alkyl, —C(O)OH, or a five membered heteroaromatic group, which rings may be substituted by lower alkyl or cycloalkyl; n is 0, 1 or 2; m is 0, 1 or 2; or a pharmaceutically acceptable acid addition salt thereof. Compound I shows high affinity and selectivity for GALA A &agr;5 receptor binding sites.
    本发明是一种化合物,其化学式为 1 其中 R 1 是卤素或较低的烷基; R 2 是氢、较低的烷基、环烷基、—(CH 2 ) m -苯基,其中苯环可能被较低的烷氧基取代,或者是—(CH 2 ) m -吲哚基; R 3 是—C(O)O-较低的烷基、—C(O)OH,或者是一个五元杂环芳基,这些环可能被较低的烷基或环烷基取代; n为0、1或2; m为0、1或2; 或其药学上可接受的酸盐。化合物I显示出对GALA A &agr;5受体结合位点的高亲和力和选择性。
  • Pharmacologically active amides, processes for their preparation and
    申请人:Rhone-Poulenc Sante
    公开号:US04788199A1
    公开(公告)日:1988-11-29
    Amides of formula: ##STR1## in which A is ##STR2## V and W are H, halogen, alkyl (1-3C), alkoxy (1-3C), NO.sub.2 or CF.sub.3, Z is bound in the ortho or para position with respect to B and is phenyl, optionally substituted, thienyl or pyridyl, the chain X--(CH.sub.2).sub.n --(CHR).sub.m --CO--NR.sub.1 R.sub.2 is bound in the ortho or para position with respect to B, R is H or alkyl (1-3C), R.sub.1 and R.sub.2 are alkyl (1-6C), cycloalkyl (3-6C), phenyl, phenylalkyl, cycloalkylalkyl, alkenyl (3-6C), R.sub.1 and R.sub.2 can also form, with the nitrogen atom to which they are attached, a pyrrolidine, piperidine, morpholine or thiomorpholine ring, X is >CH--R.sub.3, >N--R.sub.4, >SO, >SO.sub.2, >O or >S, R.sub.3 is H, alkyl (1-3C), R.sub.4 is alkyl (1-3C) m=0 or 1 and n=0, 1 or 2, provided that, if X is >SO, >SO.sub.2 or >N--R.sub.4 , the sum m+n is equal to at least 1, that, when A and B are N and Z is in the para position with respect to B, X cannot denote the group >CH--R.sub.3 and that when A is CH, B is N, Z is in the ortho position with respect to B, X is an oxygen atom, and R is a hydrogen atom, the sum m+n is other than 1, and excluding 2-phenyl-4-quinolyl N,N-dimethylcarbamate, have useful pharmacological activity, e.g. as anxiolytics, anticonvulsants and antiangina agents.
    公式为:##STR1## 中,A为##STR2##,V和W为H,卤素,烷基(1-3C),烷氧基(1-3C),NO.sub.2或CF.sub.3,Z与B的正交或相对位置相连,为苯基,可选择性取代,噻吩基或吡啶基,链X--(CH.sub.2).sub.n--(CHR).sub.m--CO--NR.sub.1 R.sub.2与B的正交或相对位置相连,R为H或烷基(1-3C),R.sub.1和R.sub.2为烷基(1-6C),环烷基(3-6C),苯基,苯基烷基,环烷基烷基,烯基(3-6C),R.sub.1和R.sub.2还可以与它们附着的氮原子形成吡咯烷,哌嗪,吗啉或硫代吗啉环,X为>CH--R.sub.3,>N--R.sub.4,>SO,>SO.sub.2,>O或>S,R.sub.3为H,烷基(1-3C),R.sub.4为烷基(1-3C),m=0或1,n=0,1或2,前提是,如果X为>SO,>SO.sub.2或>N--R.sub.4,则m+n之和至少为1,当A和B为N且Z与B的相对位置为para时,X不能表示为>CH--R.sub.3,当A为CH,B为N,Z与B的相对位置为ortho时,X为氧原子,R为氢原子,m+n之和不为1,并且不包括2-苯基-4-喹啉基N,N-二甲基氨基甲酸酯,具有有用的药理活性,例如作为抗焦虑药,抗癫痫药和抗心绞痛药。
  • Pharmacologically active amides and pharmaceutical compositions
    申请人:Rhone-Poulenc Sante
    公开号:US04788204A1
    公开(公告)日:1988-11-29
    Amides of formula: ##STR1## in which A is ##STR2## V and W are H, halogen, alkyl (1-3C), alkoxy (1-3C), NO.sub.2 or CF.sub.3, Z is bound in the ortho or para position with respect to B and is phenyl, optionally substituted, thienyl or pyridyl, the chain X-(CH.sub.2).sub.n --(CHR).sub.m --CO--NR.sub.1 R.sub.2 is bound in the ortho or para position with respect to B, R is H or alkyl (1-3C), R.sub.1 and R.sub.2 are alkyl (1-6C), cycloalkyl (3-6C), phenyl, phenylalkyl, cycloalkylalkyl, alkenyl (3-6C), R.sub.1 and R.sub.2 can also form, with the nitrogen atom to which they are attached, a pyrrolidine, piperidine, morpholine or thiomorpholine ring, X is >CH--R.sub.3, >N--R.sub.4, >SO, >SO.sub.2, >O or >S, R.sub.3 is H, alkyl (1-3C), R.sub.4 is alkyl (1-3C) m=0 or 1 and n=0, 1 or 2, provided that, if X is >SO, >SO.sub.2 or >N--R.sub.4, the sum m+n is equal to at least 1, that, when A and B are N and Z is in the para position with respect to B, X cannot denote the group >CH--R.sub.3 and that when A is CH, B is N, Z is in the ortho position with respect to B, X is an oxygen atom, and R is a hydrogen atom, the sum m+n is other than 1, and excluding 2-phenyl-4-quinolyl N,N-dimethylcarbamate, have useful pharmacological activity, e.g. as anxiolytics, anticonvulsants and antiangina agents.
    公式为:##STR1## 其中A为##STR2## V和W为H,卤素,烷基(1-3C),烷氧基(1-3C),NO.sub.2或CF.sub.3,Z与B的正交或平行位置相结合,其为苯基,可选择性取代,噻吩基或吡啶基,链X-(CH.sub.2).sub.n --(CHR).sub.m --CO--NR.sub.1 R.sub.2与B的正交或平行位置相结合,R为H或烷基(1-3C),R.sub.1和R.sub.2为烷基(1-6C),环烷基(3-6C),苯基,苯基烷基,环烷基烷基,烯基(3-6C),R.sub.1和R.sub.2还可以与它们附着的氮原子形成吡咯烷,哌嗪,吗啉或硫代吗啉环,X为>CH--R.sub.3,>N--R.sub.4,>SO,>SO.sub.2,>O或>S,R.sub.3为H,烷基(1-3C),R.sub.4为烷基(1-3C),m=0或1,n=0,1或2,前提是,如果X为>SO,>SO.sub.2或>N--R.sub.4,则m + n的总和至少为1,当A和B为N且Z相对于B在para位置时,X不能表示为>CH--R.sub.3,当A为CH,B为N,Z相对于B在ortho位置时,X为氧原子,R为氢原子,m + n的总和不为1,并且不包括2-苯基-4-喹啉基N,N-二甲基氨基甲酸酯,具有有用的药理活性,例如作为抗焦虑药,抗癫痫药和抗心绞痛药。
  • Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
    申请人:Hoffmann-La Roche Inc.
    公开号:US06686352B2
    公开(公告)日:2004-02-03
    The present invention is a compound of formula wherein R1 is halogen or lower alkyl; R2 is hydrogen, lower alkyl, cycloalkyl, —(CH2)m-phenyl, wherein the phenyl ring may be substituted by lower alkoxy, or is —(CH2)m-indolyl; R3 is —C(O)O-lower alkyl, —C(O)OH, or a five membered heteroaromatic group, which rings may be substituted by lower alkyl or cycloalkyl; n is 0, 1 or 2; m is 0, 1 or 2; or a pharmaceutically acceptable acid addition salt thereof. Compound I shows high affinity and selectivity for GALA A &agr;5 receptor binding sites.
    本发明涉及一种化合物,其化学式为:其中,R1为卤素或低碳基;R2为氢,低碳基,环烷基,-(CH2)m-苯基,其中苯环可以被低碳氧基取代,或者为-( )m-吲哚基;R3为-C(O)O-低碳基,-C(O)OH,或者为五元杂环芳基,该环可以被低碳基或环烷基取代;n为0、1或2;m为0、1或2;或其药学上可接受的酸加合物盐。化合物I显示出对GALA A &agr;5受体结合位点具有高亲和力和选择性。
  • IMIDAZO 1,5-A] PYRIMIDO 5,4-D] BENZAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS
    申请人:F. Hoffmann-La Roche AG
    公开号:EP1399448B1
    公开(公告)日:2004-12-01
查看更多